Eli Lilly’s weight-loss drug cuts diabetes risk, long-term study finds – GLOBAL

August 20, 2024

The drug tirzepatide, made popular for its treatment of Type 2 diabetes and weight loss, lowers the risk of progression to diabetes by 94 per cent among adults with prediabetes and obesity or who are overweight when taken weekly, according to a new study by the drugmaker Eli Lilly.

While the study has not yet been peer-reviewed, experts who spoke with Global News for their views on its findings said the data so far suggests the possibility of risk reduction over the course of years to come.

Results of the three-year study of the drug, also known by its brand names Mounjaro and Zepbound, were released on Tuesday with the report showing weekly injections of any of the three dosage amounts — five, 10 and 15 milligrams — “significantly reduced” the risk of progression, and also saw sustained weight loss.

Read more: https://globalnews.ca/news/10706806/eli-lilly-weight-loss-drug-zepbound-mounjaro-diabetes-risk/